Recent clinical trials raised concerns regarding the cardiovascular toxicity of selective cyclooxygenase-2 (COX-2) inhibitors and COX-1 is now being reconsidered as a target for chemoprevention. Our aims were to determine whether selective COX-1 inhibition could delay or prevent cancer development and also clarify the underlying mechanisms.
Introduction
Colorectal cancer is the third most common non-cutaneous malignancy and also the third leading cause of cancer-related death in the United States (1) . Fortunately, during colorectal carcinogenesis, the transition from normal mucosa to adenoma and final carcinoma is a protracted event that offers opportunities for preventive interventions.
Chemoprevention by targeting cyclooxygenase-2 (COX-2) has been used successfully and appears to be a promising strategy for prevention of colorectal cancer (2) (3) (4) . However, recent clinical trial studies raised concerns regarding the cardiovascular toxicity of selective COX-2 inhibitors (5-6). Animal model studies further revealed that COX-2 plays a crucial role in cardio-protection (7) (8) (9) (10) , and thus persistent COX-2 inhibition might not be an ideal chemopreventive strategy.
Although evidence implicates a crucial role of COX-2 in colorectal cancer development, the idea that COX-2 is the only COX isoform involved in carcinogenesis has been challenged. For example, aspirin at low doses (81 mg per day) is widely accepted to be able to provide both cardioprotective and colon cancer chemopreventive effects (11) (12) (13) . However, pharmacokinetic data analysis revealed that low doses of aspirin mainly target COX-1 rather than COX-2 (14) (15) . Genetic disruption of ptgs-1 (gene encoding for cyclooxygenase-1 (COX-1)) or ptgs-2 (gene encoding for COX -2) reduces intestinal polyposis to a similar extent (16) (17) . Importantly, targeting COX-1 was effective in preventing not only colon cancer but also other tumor types such as skin cancer and ovarian cancer (17) (18) Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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Thus, COX-1 is now being reconsidered as a target for chemoprevention (19) (20) . To gain a deeper insight into the role of COX-1 in human cancer development, we used a ligand docking computational method to identify a novel selective COX-1 inhibitor, 6-C-(E-phenylethenyl)-naringenin (i.e., 6CEPN). We then evaluated its chemopreventive activity against colon cancer both in vitro and in vivo.
Materials and Methods

Reagents and chemicals
6CEPN was chemically synthesized as described previously (21) . CNBr-Sepharose 4B beads were purchased from Amersham Pharmacia Biotech (Peapack, NJ). All primary antibodies were purchased from Cell Signaling Technology (Beverley, MA). All other chemicals were obtained from Sigma-Aldrich (St. Louis, MO) unless otherwise specified.
Cell culture
All cell lines used in this study were obtained from the American Type Culture Collection (ATCC, Manassas, VA) and maintained following ATTC instructions. Cells were cytogenetically tested and authenticated before being frozen. Each vial of frozen cells was thawed and maintained for a maximum of 20 passages. 
Cell transfection
For either transient or lentiviral transfection in adherent cells, the jetPEI reagent (Qbiogen, Inc., Montreal, Quebec, Canada) was used following the manufacturer's instructions. Full-length cDNAs for COX-1 and COX-2 (pCMV-SPORT6-COX-1 and pCMV-SPORT6-COX-2) and the 29-mer small hairpin RNA (shRNA) constructs against COX-1 and COX-2 were from Open Biosystems, Inc. (Huntsville, AL).
Cell growth assay
Cells were seeded (1×10 
Anchorage-independent cell growth
In each well of a 6-well plate, cells (8×10 3 ) were suspended in Basal Medium Eagle (BME) medium (1 mL, with 10% FBS and 0.33% agar) and plated over a layer of solidified BME (3 mL, with 10% FBS and 0.5% agar). The cultures were incubated in a 37°C, 5% CO 2 incubator for 7 d and colonies in soft agar were counted under a microscope equipped with the Image-Pro Plus software program (vs. 6, Media Cybernetics, Bethesda, MD). 
In vitro pull-down assay
Recombinant COX-1 and COX-2 (0.5 µg) or endogenous cell lysates (500 µg) were incubated with 6CEPN-Sepharose 4B beads (100 µL, 50% slurry) in reaction buffer (50 mM Tris pH 7.5, 5 mM EDTA, 150 mM NaCl, 1 mM DTT, 0.01% NP40, 2 µg/mL bovine serum albumin, 0.02 mM phenylmethysulfonyl fluoride (PMSF), 1× protease inhibitor mixture). Incubation with gentle rocking was performed overnight at 4°C. The beads were then washed a total of 5 times with washing buffer and proteins bound to the beads were analyzed by Western blotting.
In vitro COX enzyme assay
The effect of 6CEPN on COX activity was evaluated using a COX Inhibitor Screening 15 min, and the resulting supernatant fraction was designated as serum.
Molecular modeling
The 3-D structures of COX-1 and COX-2 were directly downloaded from the Protein Data Bank (PDB) for docking studies. COX-1 (PDB code 3KK6) is an X-ray diffraction structure with a resolution of 2.75 Å and COX-2 (PDB code 1PXX) is an X-ray diffraction structure with a resolution of 2.9 Å. The proteins were prepared for docking following the standard procedure outlined with the Protein Preparation Wizard in Schrödinger Suite 2012. All crystallographic waters were deleted and a 30-Å grid was generated on both COX-1 and COX-2 active sites to define the protein receptor for docking following the standard procedure outlined in Schrödinger's GLIDE docking package. The Zinc natural database, FDA approved drug database, Traditional Chinese Medicine (TCMD), a flavonoid compound database, and our in-house library of compounds were each used in the virtual screening.
Statistical analysis
All cell line experiments were performed independently at least 3 times. Statistical 
Results
COX-1 is required for maintaining colorectal cancer cell malignant characteristics
To determine whether COX-1 is directly associated with the tumorigenic properties of colon cancer cells, we first examined COX expression in normal and colon cancer cells (Fig. 1A) . Consistent with previous reports (22) (23) , COX-1 is present both in normal and malignant colon cancer cells, whereas COX-2 is overexpressed only in colorectal cancer cells. Among the cell lines tested, HT29, HCT115 and DLD1 cells expressed relatively higher COX-1 levels, and were therefore chosen for subsequent studies.
Anchorage-independent growth ability is an ex vivo indicator and a key characteristic of the transformed cell phenotype (24) . We thus questioned whether COX-1 inhibition would affect colon cancer cell growth under anchorage-independent conditions. Our results revealed that knocking down COX-1 expression in HT29 and HCT115 cells significantly decreased the number of colonies formed in soft agar compared with Mock-control cells (Fig. 1B) .
We also compared the function of COX-1 with COX-2 in human colon cancer cells.
Our results revealed that knocking down the expression of either COX-1 or COX-2 delayed cell growth, reduced the number of colonies formed in soft agar, and decreased PGE 2 production in HT29 cells (Fig. 1C) . Consistent with our findings, a previous animal study also indicated that both COX-1 and COX-2 contribute to PGE 2 production in polyp formation (16) .
Involvement of COX-1 in neoplastic transformation
Based on the finding showing that knockdown of COX-1 greatly abrogated anchorage-independent cell growth, we hypothesized that COX-1 might also be involved in neoplastic transformation. The JB6 CI41 cell model is a promotion sensitive (P+) mouse epidermal skin cell line that provides a unique cell model to characterize the role of COX-1 in preneoplastic cells (25) (26) . We established two stable JB6 CI41 clones that express an shRNA targeting mouse COX-1 ( Fig. 2A) , and then tested the effects of COX-1 inhibition on tumor promoter (TPA or EGF)-induced cell transformation. Results indicated that either EGF-or TPA-induced cell transformation was markedly attenuated by knockdown of COX-1 (Fig. 2B) . Additional results indicated that with EGF stimulation, EGFR downstream signaling cascades were substantially suppressed in the absence of COX-1 (Fig. 2C) .
Taken together, these findings indicated that COX-1 is required for both the maintenance of cancer cell malignant characteristics and neoplastic transformation.
The predicted binding mode of 6-C-(E-phenylethenyl)-naringenin with COX-1
Although COX-1 is now being reconsidered as a target for colorectal cancer chemoprevention, only a few selective COX-1 inhibitors have been found (19 
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identify a novel potent selective COX-1 inhibitor, we conducted an intensive molecular docking analysis using Glide v5.7 (16) . We screened several libraries of compounds and 6-C-(E-phenylethenyl)-naringenin (6CEPN; Fig. 3A ) was identified as a potential selective COX-1 inhibitor based on its docking scores against COX-1 and -2, respectively.
Our computational modeling data clearly showed that 6CEPN could only bind to the COX-1 active site by forming 3 hydrogen bonds with Tyr355, Phe518 and Ser530 (Fig.   3B ). This compound failed to bind to the COX-2 catalytic pocket due to a potential steric-hindrance effect-a phenomenon in which the enzyme is inaccessible to substrates with an improper molecular size as well as shape (Fig. 3C, left panel) . However, even though 6CEPN failed to occupy the active pocket of COX-2, it still might bind to COX-2 in another region (i.e., His 207 and His388) (Fig. 3C, right panel) .
To validate the computational prediction, we performed an in vitro pull-down assay using 6CEPN-conjugated Sepharose 4B beads (Fig. 3D) . Results revealed that both recombinant COX-1 and COX-2 bind with 6CEPN-Sepharose 4B beads, but not with Sepharose 4B beads alone in vitro. We then examined the potential inhibitory effect of 6CEPN against COX-1 and COX-2 enzyme activity using a COX inhibitor screening assay kit. Our data confirmed that 6CEPN selectively inhibited COX-1, but not COX-2, activity in vitro (Fig. 3E) . These results clearly support our hypothesis that 6CEPN is a selective COX-1 inhibitor. 
6CEPN suppresses human colorectal cancer cell growth
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Next, we determined whether 6CEPN could selectively inhibit COX-1 activity in cells. Human embryonic kidney HEK293T cells were transiently transfected with a COX-1 or COX-2 plasmid (Fig. 4A, left panels) and then treated with 6CEPN. Data regarding PGE 2 release in supernatant fractions clearly indicated that 6CEPN selectively inhibited COX-1 activity rather than COX-2, especially at low doses (Fig. 4A, right   panel) . We also confirmed that 6CEPN binds to endogenous COX-1 (Fig. 4B, left panels) and lowers PGE 2 production in colon cancer cells (Fig. 4B, right panel) . Moreover, 6CEPN potently inhibited anchorage-independent growth in a dose-dependent manner (Fig. 4C ) in 3 colon cancer cell lines. 6CEPN at 2.5 or 5 μΜ caused a decrease of more than 70-90% compared with untreated control HT29 cells, which highly express COX-1.
Evaluation of cardiovascular toxicity of 6CEPN
Next, we evaluated the potential cardiovascular toxicity of 6CEPN in an in vitro model using human umbilical vein endothelial cells (HUVECs). Although undetectable under normal physiological conditions, COX-2 is markedly induced and exerts a cardiac protective role under pathophysiological conditions such as during cardiac ischemia or reperfusion injury. The imbalance between COX-1-derived pro-thrombotic thromboxane A 2 (TXA 2 ) and COX-2-relateded antithrombotic prostacyclin (PGI 2 ) production is suspected to contribute to the cardiovascular side effects of selective COX-2 inhibitors.
Additionally, the ratio of TXB 2 (i.e., the stable breakdown product of TXA 2 ) to 6-keto-PGF 1α (i.e., the hydrolysis product of PGI 2 ) has been used as one of the biomarkers for COX-2 inhibition-related cardiovascular toxicity (7, 9-10, 19-20, 27-28) .
To mimic pro-inflammatory conditions, HUVECs were treated with IL-1β, an inflammatory cytokine implicated in vascular diseases. IL-1β stimulation resulted in a remarkable increase in COX-2 expression as well as 6-keto-PGF1 α synthesis (Fig. 5A) .
6CPEN, but not celecoxib, had a modest but significant inhibitory effect on TXB 2 synthesis (Fig. 5B, middle panels) . In contrast, celecoxib, but not 6CPEN, could potently suppress 6-keto-PGF1 α synthesis (Fig. 5B, lower panels) . More importantly, the ratio of TXB 2 /6-keto-PGF 1α was significantly (p < 0.001) increased by the selective COX-2 inhibitor celecoxib even at very low doses (e.g., 0.1 µM), but only weakly disturbed by 6CEPN (Fig. 5B, upper panels) , suggesting that cardiovascular toxicity is caused by celecoxib but not by 6CEPN.
6CEPN suppresses tumor growth by inhibiting COX-1 activity in vivo
Based on both in vitro and ex vivo data, we determined whether 6CEPN could suppress tumor growth in vivo. Results (Fig. 6A) indicated that 28 days of continuous 6CEPN treatment (10 or 40 mg/kg body weight) by gavage significantly reduced tumor volume by 31% or 59%, respectively. Similar inhibitory effects were observed on final tumor mass (Fig. 6B) . Classic COX-1 inhibitors such as aspirin and ibuprofen are known exert their cardio-protective activity by inhibiting platelet COX-1 activity, resulting in decreased synthesis of TXA 2 , but not PGI 2 (13, 19, (27) (28) . Similar results were obtained with 6CEPN treatment in this study (Fig. 6C) . Importantly, the ratio of TXB 2 6-keto-PGF 1α was greatly attenuated by continuous 6CEPN treatment, suggesting that 6CEPN might provide cardio-protective effects. Moreover, based on body weight data (Fig. 6D) , general appearance and organ histology, 6CEPN was well-tolerated in mice and no obvious systemic toxicity (e.g., diarrhea or bleeding in the digestive tract) was observed during the entire period of drug treatment.
Discussion
In this study, we confirmed a critical role for COX-1 in colorectal cancer.
Phenotypically, COX-1 knockdown or catalytic inactivation in colon cancer cells resulted in an obvious reduction of malignant characteristics, including anchorage-dependent and -independent cell growth as well as in the production of endogenous PGE 2 . Importantly, COX-1 was also required for genotoxic carcinogen-induced malignant transformation in pre-neoplastic cells. All of these findings provided an explanation as to why genetic disruption of ptgs-1 reduces cancer incidence both in skin and colon.
Although more attention has been given to COX-2 as a key player in the development of various cancers, accumulating evidence indicates that COX-1 is equally as important as COX-2 for carcinogenesis, especially in skin and colon (16) (17) . The immediate-early phase of prostaglandin production is reportedly mediated by constitutive expression of COX-1, whereas the later phase of prostaglandin production is dependent on the induction of COX-2 (29) . On the other hand, PGE 2 EGF-like ligand (30) , while activation of EGFR might conversely stimulate COX-2 biosynthesis (31). Overall, our data suggest the possibility that both COX-1 and COX-2 contribute to colon cancer development by cooperating with the EGFR signaling pathway, which modulates tumorigenesis through multiple biological effects including anchorage independent cell growth (32) . Therefore, although COX-1 is generally described as constitutively expressed both in malignant and normal colon tissues, this might be an oversimplification because the COX enzymes are known to function in the production of prostaglandins, which is either due to increased protein expression, catalytic activity, or both (27) .
In the present study, we successfully applied a ligand docking computational method and discovered a novel selective COX-1 inhibitor (6CEPN). Notably, 6CEPN, chemically appears to be a natural product-based compound, a hybrid molecule of stilbene with a flavonoid structure. Compared with other known COX-1 inhibitors, it has a unique carbon skeleton that might present a new leading COX-1 inhibitor (19, 27, 33) . To identify compounds that show higher selective COX-1 inhibition, more structure-activity studies are needed. (19) (20) 27) . However, no direct evidence exists to support selective inhibition of COX-1 as the cause of gastrointestinal side effects. Notably, homozygous ptgs-1 (genes coding for COX-1) mutant mice do not exhibit gastric lesions even though their PGE 2 production in the gastrointestinal tract is just 1% that of wildtype mice (16) . Pharmacological inhibition of COX further suggested that inhibition of both COX-1 and COX-2 was required for NSAIDs-induced gastrointestinal toxicity. In the Wistar rat, neither a selective COX-1 inhibitor (SC560) nor a COX-2 inhibitor (celecoxib) could cause obvious gastric damage. However, their combination results in severe gastrointestinal side effects (34) . In the present study, our COX-1 inhibitor, 6CEPN, was also well tolerated in mice, and no obvious GI toxicity (e.g., diarrhea and bleeding in digestive tract) was observed during the entire period of drug treatment. 
